euroPLX 47 Geneva

Registration Fee and Conditions

Delegates' Comments

"…many have attended 20 or 30 times or more…"
Dr. Norbert Rau

"…have achieved a number of successful deal outcomes…"
Paul Phull

"…four times as much for half the price…"
Anke Rau and Dr. Norbert Rau

"euroPLX is sometimes tough and intense…"
Sebastien Sanial and Malgorzata Derewianka

"…a very efficient way to meet in one-to-one meetings…"
Dr. Peter Komnick and Dr. Silke Behne

"We are Platinum Sponsors of euroPLX 49 Istanbul, because…"
Rich DiCicco

"We became a returning attendee as we've never left empty-handed…"
Kees Trommelen

"…get focused on the business...just business!"
Dragan Lutz and Mario Vlasic

"I have successfully used the euroPLX meetings for licensing-in and licensing-out…"
Dr. Satyendra Kumar

"…meet your business partners at the well organized events…"
Peter van Hoogstraten and Paul C. Borghouts

"…a highly effective and pleasant way to meet…"
Ronald Kriek and Wouter Hanegraaf

"…interact with so many companies…"
Simona Aganovic and Guy Clark

"We get value for our money…"
Vilas Nagare and Sundeep V. Bambolkar

"It’s the best partnering event…"
Jinang Parekh and Vijay Agarwal

"…the only partnering conference that covers all aspects of business development…"
Dr. Hubert Ridolphi and Dr. Gerrit Hagens

"…no better event than euroPLX to enlarge your network in the
pharmaceutical business…"
Gilbert Adatte

"...good place to expand your international network..."
Ramon Brusco

"…we wouldn’t do that if there were no results!"
Patrick Tichy

"…one of the few events which attracts a cross section of attendees from all pharmaceutical sectors…"
Daniel Jones

"…the best time and cost effective way to meet new partners."
Nuray Acar and Mutlu Topal

"There is no end to new challenges at euroPLX"
Ruud Koolen

"…a basis for excellent business."
Ana Paula Branco and José Roberto Pereira

"euroPLX is the most cost-effective and time-saving way…"
David Zubeldía

"…euroPLX is the perfect place…"
Gustavo Samojeden and Hernán Bouzada

"…good opportunity for meeting with many relevant players…"
Dietmar Jannaschk and Gemma Mogas

"…a tremendous opportunity to meet new partners…"
Marc Alvarez

"…efficient and fruitful one-to-one discussions…"
Sylvie Fondanayche

"We are not aware of any other event where you can meet so many interesting partners…"
Holger and Kai Schleenhain

"I rate euroPLX very high…"
Reynhardt Van As

"euroPLX is the best pharma meeting…"
Santiago, Mar, and Josémaria Calzada

"…very good opportunity to meet existing and new business partners…"
Agnes Olszanowski and Dr. Marian Takac

"I never leave euroPLX empty-handed."
Wendell Clayton

"…the best possible way to contact a large number of people…" Shala Fardaei and Ineke Braat

"It was in this forum that we forged some of our major alliances…" Nimit Jhaveri and Biplab Kar

"…we have made a lot of money on euroPLX deals…"
Rich DiCicco

"…an ideal opportunity to meet…"
Andreas Wagner & Michel Blanc

"…extremely time and cost efficient way to make new business contacts…"
Wolfgang Bäurle

"euroPLX is the most efficient event I know…"
Patsy Carney

"…the most efficient of the Business Development forums…"
Roland Brown

"…a tremendous opportunity to network intensely…"
Elzbieta Weston & Jacek Plucienniczak

Sponsors for euroPLX 47

Media Sponsors

Another Successful euroPLX Meeting!

euroPLX 47 Geneva

Almost 90% of all appointments requests were met by RauCon's priority based scheduling system.

Click to view registered companies

After a few last minute cancellations 110 companies from 35 countries attended euroPLX 47 Geneva which was held on 21 and 22 November 2011 in the Hotel InterContinental Genève, Switzerland. An average of 23.4 appointments were scheduled for each company and RauCon's priority based scheduling system was able to schedule 88.3% of all requests in spite of the short availability of many participants.

The participants' main focus was on deals involving prescription drugs for hospitals and practitioners. OTC drugs ranked second and food supplements third although 33% of the companies were interested in the latter. Interest in pain, CNS and neurology drugs was highest, followed by oncologicals and cardiovasculars.